Home » Rare respiratory diseases, the biotech Kither closes an 18.5 million round

Rare respiratory diseases, the biotech Kither closes an 18.5 million round

by admin
Rare respiratory diseases, the biotech Kither closes an 18.5 million round

Kither Biotech, a biopharmaceutical company developing new therapies for rare respiratory diseases, announces that it has raised € 18.5 million in a Series B funding round and has named current board member Vincent Metzler as CEO.

The proceeds will be used to fund the clinical development of Kither’s core product, KIT2014, a novel cell-permeable peptide for the treatment of cystic fibrosis that modulates levels of cyclic adenosine monophosphate (cAMP) – a cellular metabolite – within cells. .

Levels of cAMP are directly associated with the pathogenesis of cystic fibrosis, including mucus accumulation, inflammation and bronchoconstriction. The drug is administered directly to the lungs as inhalation therapy and is currently under development as an adjunct to the current standard therapy, allowing it to be more effective in reducing the most significant ailments in cystic fibrosis patients.

The company plans to complete preclinical studies in 2022 and begin a Phase 1 / 2A clinical trial soon after. The funding round will also allow Kither to begin expanding and diversifying its pipeline of products for the treatment of rare lung diseases and to launch preclinical development of a small molecule inhibitor (KITCL27) of the PI3K enzyme that acts in the form of a pro-drug and which is being developed as a monotherapy for idiopathic pulmonary fibrosis.

The fundraising was conducted by new investors Claris Ventures and 2Invest, with the participation of 3B Future Health Fund and Alef 6. Existing investors Cdp Venture Capital Sgr, Italian Angels for Growth, Ersel, Club degli Investitori and Ace Venture joined to the funding round.

You may also like

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy